Target Price | €52.02 |
Price | €41.34 |
Potential | 25.83% |
Number of Estimates | 23 |
23 Analysts have issued a price target Fresenius Medical Care 2026 . The average Fresenius Medical Care target price is €52.02. This is 25.83% higher than the current stock price. The highest price target is €65.10 57.47% , the lowest is €26.12 36.81% . | |
A rating was issued by 25 analysts: 9 Analysts recommend Fresenius Medical Care to buy, 12 to hold and 4 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Fresenius Medical Care stock has an average upside potential 2026 of 25.83% . Most analysts recommend the Fresenius Medical Care stock at Hold. |
24 Analysts have issued a sales forecast Fresenius Medical Care 2025 . The average Fresenius Medical Care sales estimate is €19.8b . This is 1.42% higher than the revenue of the last 12 months(TTM). The highest sales forecast is €21.1b 8.08% , the lowest is €18.7b 4.16% .
This results in the following potential growth metrics:
2024 | €19.3b | 0.61% |
---|---|---|
2025 | €19.8b | 2.38% |
2026 | €20.5b | 3.41% |
2027 | €21.3b | 4.03% |
2028 | €22.4b | 5.03% |
2029 | €23.4b | 4.41% |
2030 | €24.9b | 6.47% |
2031 | €24.9b | 0.12% |
2032 | €25.8b | 3.56% |
21 Analysts have issued an Fresenius Medical Care EBITDA forecast 2025. The average Fresenius Medical Care EBITDA estimate is €3.7b . This is 21.58% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is €4.1b 37.00% , the lowest is €2.7b 11.90% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | €3.0b | 0.73% |
---|---|---|
2025 | €3.7b | 21.57% |
2026 | €3.9b | 7.19% |
2027 | €4.1b | 4.74% |
2028 | €4.1b | 0.22% |
2029 | €4.3b | 3.86% |
2030 | €4.7b | 10.69% |
2031 | €5.0b | 5.09% |
2032 | €5.2b | 3.88% |
2024 | 15.56% | 0.12% |
---|---|---|
2025 | 18.47% | 18.72% |
2026 | 19.15% | 3.68% |
2027 | 19.28% | 0.68% |
2028 | 18.40% | 4.56% |
2029 | 18.30% | 0.54% |
2030 | 19.03% | 3.99% |
2031 | 19.97% | 4.94% |
2032 | 20.03% | 0.30% |
25 Fresenius Medical Care Analysts have issued a net profit forecast 2025. The average Fresenius Medical Care net profit estimate is €1.1b . This is 65.64% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is €1.3b 99.00% , the lowest is €624m 4.94% .
This results in the following potential growth metrics and future Net Margins:
2024 | €538m | 7.80% |
---|---|---|
2025 | €1.1b | 102.13% |
2026 | €1.2b | 10.29% |
2027 | €1.4b | 15.04% |
2028 | €1.6b | 16.37% |
2029 | €1.7b | 8.91% |
2030 | €2.2b | 24.23% |
2031 | €2.0b | 6.11% |
2032 | €2.2b | 7.75% |
2024 | 2.78% | 8.45% |
---|---|---|
2025 | 5.49% | 97.35% |
2026 | 5.86% | 6.74% |
2027 | 6.48% | 10.58% |
2028 | 7.18% | 10.80% |
2029 | 7.49% | 4.32% |
2030 | 8.74% | 16.69% |
2031 | 8.19% | 6.29% |
2032 | 8.52% | 4.03% |
25 Analysts have issued a Fresenius Medical Care forecast for earnings per share. The average Fresenius Medical Care EPS is €3.71 . This is 65.63% higher than earnings per share in the financial year 2024. The highest EPS forecast is €4.45 98.66% , the lowest is €2.13 4.91% .
This results in the following potential growth metrics and future valuations:
2024 | €1.83 | 7.65% |
---|---|---|
2025 | €3.71 | 102.73% |
2026 | €4.09 | 10.24% |
2027 | €4.70 | 14.91% |
2028 | €5.47 | 16.38% |
2029 | €5.96 | 8.96% |
2030 | €7.40 | 24.16% |
2031 | €6.95 | 6.08% |
2032 | €7.49 | 7.77% |
Current | 18.51 | 0.21% |
---|---|---|
2025 | 11.19 | 39.54% |
2026 | 10.14 | 9.38% |
2027 | 8.82 | 13.02% |
2028 | 7.58 | 14.06% |
2029 | 6.96 | 8.18% |
2030 | 5.60 | 19.54% |
2031 | 5.97 | 6.61% |
2032 | 5.54 | 7.20% |
Based on analysts' sales estimates for 2025, the Fresenius Medical Care stock is valued at an EV/Sales of 1.06 and an P/S ratio of 0.61 .
This results in the following potential growth metrics and future valuations:
Current | 1.07 | 2.88% |
---|---|---|
2025 | 1.06 | 1.29% |
2026 | 1.02 | 3.30% |
2027 | 0.98 | 3.87% |
2028 | 0.93 | 4.80% |
2029 | 0.90 | 4.22% |
2030 | 0.84 | 6.09% |
2031 | 0.84 | 0.11% |
2032 | 0.81 | 3.44% |
Current | 0.62 | 21.92% |
---|---|---|
2025 | 0.61 | 1.41% |
2026 | 0.59 | 3.30% |
2027 | 0.57 | 3.88% |
2028 | 0.54 | 4.78% |
2029 | 0.52 | 4.22% |
2030 | 0.49 | 6.07% |
2031 | 0.49 | 0.12% |
2032 | 0.47 | 3.44% |
Fresenius Medical Care...
Analyst | Rating | Action | Date |
---|---|---|---|
BERENBERG |
Buy
➜
Buy
|
Unchanged | Jun 30 2025 |
ODDO BHF |
Buy
➜
Buy
|
Unchanged | Jun 17 2025 |
MWB RESEARCH AG |
Hold
➜
Hold
|
Unchanged | Jun 17 2025 |
JEFFERIES |
Underperform
➜
Underperform
|
Unchanged | Jun 16 2025 |
METZLER EQUITIES |
Buy
➜
Buy
|
Unchanged | May 29 2025 |
HSBC |
Buy
➜
Buy
|
Unchanged | May 25 2025 |
DZ BANK |
Hold
➜
Buy
|
Upgrade | May 12 2025 |
Analyst Rating | Date |
---|---|
Unchanged
BERENBERG:
Buy
➜
Buy
|
Jun 30 2025 |
Unchanged
ODDO BHF:
Buy
➜
Buy
|
Jun 17 2025 |
Unchanged
MWB RESEARCH AG:
Hold
➜
Hold
|
Jun 17 2025 |
Unchanged
JEFFERIES:
Underperform
➜
Underperform
|
Jun 16 2025 |
Unchanged
METZLER EQUITIES:
Buy
➜
Buy
|
May 29 2025 |
Unchanged
HSBC:
Buy
➜
Buy
|
May 25 2025 |
Upgrade
DZ BANK:
Hold
➜
Buy
|
May 12 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.